CITRINE GLOBAL, CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CITRINE GLOBAL, CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | May 10, 2017 |
| FY2016 | Dec 31, 2015 | $0 | May 10, 2017 |
| FY2015 | Dec 31, 2014 | $5.8K | Apr 4, 2016 |
| FY2014 | Dec 31, 2013 | $5.8K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $5.8K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $92.9K | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | $0 | Mar 30, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $12.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $149.1K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $251.4K | May 11, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | ($2.0K) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($185.6K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $32.8K | May 11, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.92M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.30M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.11M) | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | ($2.65M) | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | ($4.52M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($8.64M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.87M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.16M | May 11, 2020 |
| FY2018 | Dec 31, 2017 | ($2.86M) | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $383.2K | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.26M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.24M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.30M) | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | ($1.99M) | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | ($3.34M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($8.32M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.84M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.13M | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $2.88M | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $388.5K | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $120.0K | Mar 22, 2023 |
| FY2022 | Dec 31, 2021 | $96.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $17.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $114.6K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $288.8K | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $282.4K | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $83.0K | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | $82.3K | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | $158.5K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $1.00M | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.87M | Mar 22, 2023 |
| FY2022 | Dec 31, 2021 | $3.24M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $8.35M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $1.54M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.00M | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $2.46M | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $398.9K | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | $309.7K | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | $1.31M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $822.9K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($468.0K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.0K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($199.0K) | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | ($567.0K) | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | ($582.0K) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($696.0K) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($1.23M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.39M) | May 11, 2020 |
| FY2018 | Dec 31, 2017 | ($1.47M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.29M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.0K | Apr 15, 2026 |
| FY2023 | Dec 31, 2022 | $4.0K | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | $252.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $6.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $11.0K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $98.0K | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $5.3K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $44.9K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.62M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.49M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.31M | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | $1.06M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $3.11M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $256.8K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.16M | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $862.4K | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $396.9K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.47M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.32M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.96M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $3.78M | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | $2.50M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $1.70M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $367.6K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $416.8K | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $351.0K | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $428.9K | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.26M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.70M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($2.48M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($2.47M) | Sep 3, 2025 |
| FY2023 | Dec 31, 2021 | ($1.44M) | Sep 3, 2025 |
| FY2022 | Dec 31, 2020 | $1.40M | Mar 22, 2023 |
| FY2021 | Dec 31, 2019 | ($410.0K) | Apr 8, 2022 |
| FY2020 | Dec 31, 2018 | $741.5K | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | $511.4K | May 11, 2020 |
| FY2017 | Sep 30, 2017 | ($32.0K) | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.72M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($31.81M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($29.51M) | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | ($26.40M) | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | ($23.76M) | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | ($19.24M) | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | ($10.60M) | Apr 15, 2021 |
| FY2019 | Sep 30, 2019 | $10.60M | May 11, 2020 |
| FY2019 | Dec 31, 2018 | ($8.73M) | May 11, 2020 |
| FY2018 | Dec 31, 2017 | ($6.57M) | Mar 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $7.0K | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | $77.0K | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | $270.0K | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | $206.0K | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | $17.6K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $474.7K | May 11, 2020 |
| FY2018 | Dec 31, 2017 | $589.8K | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | $84.3K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 22, 2023 |
| FY2019 | Dec 31, 2019 | 0 | May 11, 2020 |
| FY2019 | Dec 31, 2018 | 0 | May 11, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Sep 3, 2025 |
| FY2019 | Dec 31, 2019 | 0 | May 11, 2020 |
| FY2019 | Dec 31, 2018 | 0 | May 11, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Sep 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | 0 | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.25B | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 1.04B | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 973.70M | Sep 3, 2025 |
| FY2023 | Dec 31, 2022 | 943.70M | Sep 3, 2025 |
| FY2022 | Dec 31, 2021 | 942.57M | Mar 22, 2023 |
| FY2021 | Dec 31, 2020 | 942.57M | Apr 8, 2022 |
| FY2020 | Dec 31, 2019 | 35.45M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 33.21M | May 11, 2020 |
| FY2018 | Dec 31, 2017 | 25.84M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 20.38M | Apr 2, 2018 |